BCRX
Biocryst Pharmaceuticals Inc
$8.46
Earnings Summary
Revenue | $40.99Mn |
Net Profits | $-58.8Mn |
Net Profit Margins | -143.44% |
Highlights
Biocryst Pharmaceuticals Inc’s revenue jumped 571.81% since last year same period to $40.99Mn in the Q3 2021. On a quarterly growth basis, Biocryst Pharmaceuticals Inc has generated -17.94% fall in its revenue since last 3-months.
Biocryst Pharmaceuticals Inc’s net profit fell -27.51% since last year same period to $-58.8Mn in the Q3 2021. On a quarterly growth basis, Biocryst Pharmaceuticals Inc has generated -36.12% fall in its net profits since last 3-months.
Biocryst Pharmaceuticals Inc’s net profit margin jumped 81.02% since last year same period to -143.44% in the Q3 2021. On a quarterly growth basis, Biocryst Pharmaceuticals Inc has generated -65.89% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Biocryst Pharmaceuticals Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.16 |
EPS Estimate Current Year | -0.16 |
Highlights
Biocryst Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.16 - a 44.83% jump from last quarter’s estimates.
Biocryst Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.16.
Key Ratios
Key ratios of the Biocryst Pharmaceuticals Inc post its Q4 2022 earnings
Return on Assets (ROA) | -0.16 |
Return on Equity (ROE) | -19.25 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Biocryst Pharmaceuticals Inc’s return on assets (ROA) stands at -0.16.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Biocryst Pharmaceuticals Inc’s return on equity (ROE) stands at -19.25.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2018-03-12 | -0.15 | -0.2 | -33.33% |
2017-11-08 | -0.19 | -0.18 | 5.26% |
2017-08-08 | -0.19 | -0.21 | -10.53% |
2017-05-08 | -0.18 | -0.19 | -5.56% |
Company Information
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing.
Organisation | Biocryst Pharmaceuticals Inc |
Headquarters | 4505 Emperor Boulevard, Durham, NC, United States, 27703 |
Employees | 531 |
Industry | Health Technology |
CEO | Jon Stonehouse |
